Malaria Eradication Program

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Admittedly, the world and the nature of forced migration have changed a great deal over the last two decades. The relevance of data accumulated during that time period can now be called into question. The roundtable and the Program on Forced Migration at the Mailman School of Public Health of Columbia University have commissioned a series of epidemiological reviews on priority public health problems for forced migrants that will update the state of knowledge. Malaria Control During Mass Population Movements and Natural Disasters- the first in the series, provides a basic overview of the state of knowledge of epidemiology of malaria and public health interventions and practices for controlling the disease in situations involving forced migration and conflict.

Malaria is making a dramatic comeback in the world. The disease is the foremost health challenge in Africa south of the Sahara, and people traveling to malarious areas are at increased risk of malaria-related sickness and death. This book examines the prospects for bringing malaria under control, with specific recommendations for U.S. policy, directions for research and program funding, and appropriate roles for federal and international agencies and the medical and public health communities. The volume reports on the current status of malaria research, prevention, and control efforts worldwide. The authors present study results and commentary on the: Nature, clinical manifestations, diagnosis, and epidemiology of malaria. Biology of the malaria parasite and its vector. Prospects for developing malaria vaccines and improved treatments. Economic, social, and behavioral factors in malaria control.

The World Health Organization's Global Technical Strategy for Malaria 2016- 2030 has been developed with the aim to help countries to reduce the human suffering caused by the world's deadliest mosquito-borne disease. Adopted by the World Health Assembly in May 2015 it provides comprehensive technical guidance to countries and development partners for the next 15 years emphasizing the importance of scaling up malaria responses and moving towards elimination. It also highlights the urgent need to increase investments across all interventions - including preventive measures diagnostic testing treatment and disease surveillance- as well as in harnessing innovation and expanding research. By adopting this strategy WHO Member States have endorsed the bold vision of a world free of malaria and set the ambitious new target of reducing the global malaria burden by 90% by 2030. They also agreed to strengthen health systems address emerging multi-drug and insecticide resistance and intensify national cross-border and regional efforts to scale up malaria responses to protect everyone at risk.

Publisher description

In 2016, at the request of the WHO Director-General, a group of scientists and public health experts from around the world were brought together to advise WHO on future scenarios for malaria, including whether eradication was feasible. Over three years, the members of the Strategic Advisory Group on Malaria Eradication (SAGme) analysed trends and reviewed future projections for the factors and determinants that underpin malaria. Our analysis and discussions reaffirmed that eradication will result in millions of lives saved and a return on investment of billions of dollars. We did not identify biological or environmental barriers to malaria eradication. In addition, our review of models accounting for a variety of global trends in the human and biophysical environment over the next three decades suggests that the world of the future will have much less malaria to contend with. However, even with our most optimistic scenarios and projections, we face an unavoidable fact: using current tools, we will still have 11 million cases of malaria in Africa in 2050. Under these circumstances, it is impossible to set a target date for malaria eradication, to formulate a reliable operational plan for malaria eradication or to give it a price tag. Our current priority should be to establish the foundation for a successful future eradication effort. At the same time, we need to guard against the risk of failure, as such failure might lead to the waste of huge sums of money, frustrate all those involved (national governments and malaria experts alike), and cause a lack of confidence in the global health community's ability to rid the world of this disease. We need a renewed drive towards research and development (R&D) on vector control, chemotherapy and vaccines in order to develop the transformative tools and knowledge base necessary for achieving eradication in the highest burden areas. We need political leadership that makes effective and efficient use of increased domestic and international funding. We need bespoke national and subnational strategies guided by improved use of data and stronger delivery systems to provide the appropriate mix of services to all those in need, without financial hardship. We need strengthened cross-border, regional and international cooperation on malaria control and elimination efforts worldwide. When these critical foundations are laid, we believe that the world will be in a much stronger position to make the final and credible push for eradication. As we complete our work in 2019, we recognize that the world stands at a crossroads in the fight against malaria. Despite huge progress in reducing malaria cases and deaths between 2000 and 2015, in the last five years, we have witnessed the stalling of global progress. The world is not on track to meet the 2020 milestones that will lead us to lower case incidence and mortality by 90% by 2030 (from 2015 levels) (5). Without massive concerted and coordinated action, we are unlikely to meet these targets. While we are certain that eradication by a specific date is not a promise we can make to the world just yet, there is a clear agenda - beginning with getting back on track to achieve the goals of the GTS - that should immediately be pursued to make eradication possible.

A global history of malaria that traces the natural and social forces that have shaped its spread and made it deadly, while limiting efforts to eliminate it. Malaria sickens hundreds of millions of people—and kills nearly a half a million—each year. Despite massive efforts to eradicate the disease, it remains a major public health problem in poorer tropical regions. But malaria has not always been concentrated in tropical areas. How did malaria disappear from other regions, and why does it persist in the tropics? From Russia to Bengal to Palm Beach, Randall M. Packard's far-ranging narrative shows how the history of malaria has been driven by the interplay of social, biological, economic, and environmental forces. The shifting alignment of these forces has largely determined the social and geographical distribution of the disease, including its initial global expansion, its subsequent retreat to the tropics, and its current persistence. Packard argues that efforts to control and eliminate malaria have often ignored this reality, relying on the use of biotechnologies to fight the disease. Failure to address the forces driving malaria transmission have undermined past control efforts. Describing major changes in both the epidemiology of malaria and efforts to control the disease, the revised edition of this acclaimed history, which was chosen as the 2008 End Malaria Awards Book of the Year in its original printing, • examines recent efforts to eradicate malaria following massive increases in funding and political commitment; • discusses the development of new malaria-fighting biotechnologies, including long-lasting insecticide-treated nets, rapid diagnostic tests, combination artemisinin therapies, and genetically modified mosquitoes; • explores the efficacy of newly developed vaccines; and • explains why eliminating malaria will also require addressing the social forces that drive the disease and building health infrastructures that can identify and treat the last cases of malaria. Authoritative, fascinating, and eye-opening, this short history of malaria concludes with policy recommendations for improving control strategies and saving lives.

For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africaâ€"currently just over one million per yearâ€"are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called "artemisinins" are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.

A fascinating and shocking historical exposé, The Malaria Project is the story of America's secret mission to combat malaria during World War II—a campaign modeled after a German project which tested experimental drugs on men gone mad from syphilis. American war planners, foreseeing the tactical need for a malaria drug, recreated the German model, then grew it tenfold. Quickly becoming the biggest and most important medical initiative of the war, the project tasked dozens of the country’s top research scientists and university labs to find a treatment to remedy half a million U.S. troops incapacitated by malaria. Spearheading the new U.S. effort was Dr. Lowell T. Coggeshall, the son of a poor Indiana farmer whose persistent drive and curiosity led him to become one of the most innovative thinkers in solving the malaria problem. He recruited private corporations, such as today's Squibb and Eli Lilly, and the nation’s best chemists out of Harvard and Johns Hopkins to make novel compounds that skilled technicians tested on birds. Giants in the field of clinical research, including the future NIH director James Shannon, then tested the drugs on mental health patients and convicted criminals—including infamous murderer Nathan Leopold. By 1943, a dozen strains of malaria brought home in the veins of sick soldiers were injected into these human guinea pigs for drug studies. After hundreds of trials and many deaths, they found their “magic bullet,” but not in a U.S. laboratory. America 's best weapon against malaria, still used today, was captured in battle from the Nazis. Called chloroquine, it went on to save more lives than any other drug in history. Karen M. Masterson, a journalist turned malaria researcher, uncovers the complete story behind this dark tale of science, medicine and war. Illuminating, riveting and surprising, The Malaria Project captures the ethical perils of seeking treatments for disease while ignoring the human condition.